Diabetics must be regularly examined by their ophthalmologist to look for leakage of blood inside the retinas of their eyes, which could result in blindness.
Now the Hebrew University of Jerusalem’s technology transfer arm, Yissum Research Development Company, has patented a method for detecting retinal microaneurysms that pose a high risk for leakage. The novel method will enable early diagnosis and treatment of the condition, potentially minimizing damage and saving vision.
Yissum presents exciting technologies at Biomed 2013
This is the largest ever fund raising round by the company, which develops camera-based advanced driver assistance systems for the automotive industry.
Yaacov Michlin, Yissum CEO says: "The key to success for biotech in Israel is starting a small company, then catching the attention of Big Pharma.
Hebrew University is preparing to establish a center for pharmaceutical research and treatment of children, the dean of HU’s School of Pharmacy, Prof.Simon Benita announced on Monday. Half-a-million dollars have already been collected towards establishing the center in the pharmacy school’s Jerusalem Ein Kerem campus.
"The sucess of the Israeli Technology Transfer companies in commercializing academic innovation is key element in Israeli's economy", says Wonjae Lee, head of the Korean office at Yozman Group.
Yissum Spin Off PlantArray places sensors on plants to monitor hundreds of them simultaniously.
Surveillance cameras were not enough to catch the Boston Marathon terrorists. The Israeli-based BriefCam firm “collapsed” an hour of video and focused on suspicious objects – and people. Briefcam, a Yissum spin-off company is a world success.
Prof. Yechezkel Barenholz, co-inventor of the Doxil drug talks of the long journey from lab to market and of his new "baby" start up- Lipocure.
Prof. Marta Weinstock-Rosin was born on the wrong side of a lot of settings: In Austria she was too Jewish, at the British Academy in the early '50s she was too much of a woman, in Israel she was considered too British and for Novartis, manufacturer of her blockbuster drug Exelon she was too Israeli.
Prof. Haim Rabinowitch tell Globes how his scientific research changed the balance of power in agricultural world markets
In parallel, Holmen, a leading manufacturer in the forest based sector, has entered into an investment and sub-licensing agreement with Melodea, by which Holmen has become one of the major shareholders in Melodea.
Investment to Support BriefCam's Global Marketing and Sales Expansion for Video Synopsis Technology
Yissum Technology Transfer Company of the Hebrew University of Jerusalemis raising $5 million to invest in agro biotechnology companies. Yissum has already closed a $5 million fund for investment in life sciences companies, and now plans to replicate the success.
Yissum Spin off RegeneCure announced today the successful results of a clinical study in pets using the company's regenerative membrane implant technology for the treatment of bone fractures. The study showed that the healing time was about 40 percent quicker than normally observed using current Standard of Care therapies. The product was also demonstrated to be safe in all of the study participants.
Drug developer Avraham Pharmaceuticals Ltd. has raised $5.7 million fromYissum Technology Transfer Company of the Hebrew University of Jerusalem.Technion Research and Development Foundation, Clal Biotechnology Industries Ltd. (TASE: CBI) and the Pontifax fund. Following the current investment round, Yissum and Integra Holdings, Yissum's biotech holdings company, will now hold 47% of the shares of Avraham Pharmaceuticals.
Israeli scientists introduce new varieties of the popular legume that retain high nutritional values and produce a better yield.
Hebrew University develops more nutritious chickpeas adapted to limited rainfall. Yissum, the university’s research and development company, has introduced new chickpea varieties that retain high nutritional values while showing improved synchronization between flowering and the rainy season, thereby increasing yield.
A serendipitous lab discovery led to a breakthrough vaccine for a fatal tick-borne disease. Now investors are sought to take it commercial